SciClone's shares dip as pancreatic cancer trial stopped
This article was originally published in Scrip
Executive Summary
SciClone Pharmaceuticals' shares took a knock earlier this week following the discontinuation of a Phase II trial evaluating RP101 (also known as BVdU), for the treatment of late-stage pancreatic cancer in response to a recommendation from the data safety monitoring committee.